Literature DB >> 12730154

Recombinant plasma gelsolin infusion attenuates burn-induced pulmonary microvascular dysfunction.

Patricia A Rothenbach1, Benny Dahl, Jason J Schwartz, Grant E O'Keefe, Masaya Yamamoto, William M Lee, Jureta W Horton, Helen L Yin, Richard H Turnage.   

Abstract

Reduced plasma concentrations of the extracellular actin-binding proteins gelsolin and Gc-globulin correlate with pulmonary failure and death in humans after injury. The purpose of this study was to investigate the role of plasma gelsolin in the pathophysiology of inflammation-induced lung injury. We postulated that plasma gelsolin levels decrease at an early time point after burn injury and that the intravenous infusion of gelsolin prevents burn-induced pulmonary microvascular dysfunction. Adult Sprague-Dawley rats were randomized to undergo a 40% body surface area thermal injury (Burn) or manipulation without burn (Sham). Plasma gelsolin and Gc-globulin concentrations were determined at various times during the first 6 days of injury by Western blotting. Other animals were randomized to receive either recombinant human gelsolin (0.078, 0.78, or 7.8 mg) or albumin (7.8 mg) before and 8 h after Burn or Sham. Twenty-four hours later, pulmonary microvascular permeability was assessed by measuring the capillary filtration by use of an isolated, perfused lung model. We found that plasma gelsolin levels of burn-injured rats decreased to 10% of normal levels within 12 h and remained below normal levels for up to 6 days postinjury. Gc-globulin values also fall, but to a lesser extent and only transiently. Treatment of burned animals with intravenous infusions of recombinant human gelsolin prevented the increase in pulmonary microvascular permeability that accompanies this injury. Our findings are consistent with the hypothesis that plasma gelsolin depletion contributes to the pathophysiology of pulmonary microvascular dysfunction during inflammation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12730154     DOI: 10.1152/japplphysiol.01074.2002

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  40 in total

1.  Plasma gelsolin and circulating actin correlate with hemodialysis mortality.

Authors:  Po-Shun Lee; Kartik Sampath; S Ananth Karumanchi; Hector Tamez; Ishir Bhan; Tamara Isakova; Orlando M Gutierrez; Myles Wolf; Yuchiao Chang; Thomas P Stossel; Ravi Thadhani
Journal:  J Am Soc Nephrol       Date:  2009-04-23       Impact factor: 10.121

Review 2.  Review article: Biomarkers of clinical outcomes in advanced chronic kidney disease.

Authors:  Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  Nephrology (Carlton)       Date:  2009-06       Impact factor: 2.506

3.  Depletion of plasma gelsolin in patients with tick-borne encephalitis and Lyme neuroborreliosis.

Authors:  Alina Kułakowska; Joanna M Zajkowska; Nicholas J Ciccarelli; Barbara Mroczko; Wiesław Drozdowski; Robert Bucki
Journal:  Neurodegener Dis       Date:  2011-03-10       Impact factor: 2.977

4.  Plasma gelsolin level predicts acute kidney injury after cardiopulmonary bypass in infants and young children.

Authors:  Shan-Shan Shi; Xiao-Jie Yue; Dong-Yan Zhao; Jia-Jie Fan; Jian-Guo Xu; Xi-Wang Liu; Bao-Li Cheng; Xiang-Ming Fang; Jie Fan; Qiang Shu
Journal:  World J Pediatr       Date:  2018-02-09       Impact factor: 2.764

5.  Low Plasma Gelsolin Concentrations in Chronic Granulomatous Disease.

Authors:  John Audley; Emily F Gliniewicz; Kol A Zarember; Hanna S Hong; Gal Wald; Douglas B Kuhns; Elizabeth Kang; Harry L Malech; Anthony F Suffredini; Robert J Noveck; Mark J Dinubile; Susan L Levinson; Thomas P Stossel; John I Gallin
Journal:  Inflammation       Date:  2020-09-04       Impact factor: 4.092

6.  Therapeutic potential of plasma gelsolin administration in a rat model of sepsis.

Authors:  Taylor S Cohen; Robert Bucki; Fitzroy J Byfield; Nicholas J Ciccarelli; Brenna Rosenberg; Mark J DiNubile; Paul A Janmey; Susan S Margulies
Journal:  Cytokine       Date:  2011-03-21       Impact factor: 3.861

7.  Gelsolin is depleted in post-shock mesenteric lymph.

Authors:  Janeen R Jordan; Ernest E Moore; Sagar S Damle; Phillip Eckels; Jeffrey L Johnson; Jonathan P Roach; Jasmina S Redzic; Kirk C Hansen; Anirban Banerjee
Journal:  J Surg Res       Date:  2007-11       Impact factor: 2.192

8.  Relationship of plasma gelsolin levels to outcomes in critically ill surgical patients.

Authors:  Po-Shun Lee; Leslie R Drager; Thomas P Stossel; Francis D Moore; Selwyn O Rogers
Journal:  Ann Surg       Date:  2006-03       Impact factor: 12.969

9.  Safety and Pharmacokinetics of Recombinant Human Plasma Gelsolin in Patients Hospitalized for Nonsevere Community-Acquired Pneumonia.

Authors:  Abla Tannous; Susan L Levinson; James Bolognese; Steven M Opal; Mark J DiNubile
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

10.  Vitamin D therapy in experimental allergic encephalomyelitis could be limited by opposing effects of sphingosine 1-phosphate and gelsolin dysregulation.

Authors:  Yanyan Zhu; Zhaoyu Qin; Jifang Gao; Mingchong Yang; Yanjiang Qin; Ting Shen; Shilian Liu
Journal:  Mol Neurobiol       Date:  2014-04-11       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.